Farhad Ravandi‐Kashani

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

Naval Daver, Guillermo Garcia‐Manero, Sreyashi Basu et al. · Cancer Discovery · 2018 · 571 citations

Medicine, Oncology, Pharmacology +17

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021

Daniel A. Pollyea, Dale L. Bixby, Alexander E. Perl et al. · Journal of the National Comprehensive Cancer Network · 2021 · 326 citations · Full text

Medicine, Hematology, Oncology +14

Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia

Apostolia M. Tsimberidou, William G. Wierda, William Plunkett et al. · Journal of Clinical Oncology · 2008 · 161 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia

Hagop M. Kantarjian, Susan O’Brien, Jianqin Shan et al. · Cancer · 2007 · 106 citations · Full text

Medicine, Hematology, Oncology +12

Augmented Berlin‐Frankfurt‐Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)

Michael Rytting, Deborah A. Thomas, Susan O’Brien et al. · Cancer · 2014 · 99 citations · Full text

Medicine, Hematology, Oncology +15